Background
University of Florida Research Foundation (UFRF) held patents on patient monitoring technology. Covidien, a medical device company that had acquired related technology from inventors who had previously assigned their patent rights to UFRF’s predecessor, sought IPR review of UFRF’s patents on validity grounds. UFRF argued that assignor estoppel barred Covidien from challenging the patents because Covidien was in privity with the inventors who had made the original assignments.
The case reached the Federal Circuit following the Supreme Court’s 2021 decision in Minerva v. Hologic, which had significantly narrowed assignor estoppel — limiting it to situations where the challenge directly contradicts a representation the assignor made to obtain the assignment consideration, rather than applying it broadly to all validity challenges by anyone in privity with the original assignor.
The Court’s Holding
The Federal Circuit applied Minerva’s narrowed assignor estoppel framework to evaluate exactly which claims Covidien was estopped from challenging. The court held that assignor estoppel applies only to validity challenges that are “inconsistent with the premise of the assignment” — meaning challenges that contradict what the assignor implicitly warranted when assigning the patent rights. For claims that existed in substantially the same form at the time of assignment, estoppel applies. For claims that were materially broadened after the assignment, estoppel does not apply because the assignor never made any warranty about those post-assignment claims.
The court remanded for the district court to apply this more nuanced, claim-by-claim analysis to determine which specific claims Covidien was estopped from challenging — requiring careful comparison between the claim scope at the time of assignment and the claim scope at the time of the validity challenge.
Key Takeaways
- Post-Minerva, assignor estoppel is applied claim-by-claim: an assignee is estopped only from challenging claims whose validity was implicitly warranted at assignment — not from challenging claims materially broadened or added after the assignment.
- Patent owners who want to use assignor estoppel to block IPR petitions from assignee competitors must show that the challenged claims substantially correspond to what existed (or was warranted) at the time of the original assignment.
- Companies acquiring patent rights from inventor-assignors should carefully audit the prosecution history to identify any claim scope expansions made after the original assignment — those post-assignment claims may be challengeable in IPR without estoppel.
- University technology transfer offices and institutional patent assignees need to understand that assignor estoppel under Minerva is narrower than it once was — it does not categorically protect all patent claims from validity challenge by parties in privity with the original assignor.
Why It Matters
The Covidien decision was one of the first Federal Circuit applications of the Supreme Court’s Minerva v. Hologic narrowing of assignor estoppel — an important doctrine in patent law that had historically prevented inventors and companies who had assigned patents from later challenging those patents’ validity. By showing how the post-Minerva framework operates in practice — requiring claim-by-claim analysis tied to the scope of what was warranted at assignment — the Federal Circuit provided concrete guidance on how to evaluate and litigate assignor estoppel questions after Minerva.
For practitioners in the medical device, life science, and technology sectors — where inventor-founders often assign patents to companies or universities and later join competitors — the decision clarified the limits of assignor estoppel as a shield against IPR challenges. Companies that acquire patents from institutional assignees (universities, research foundations, corporate predecessors) now have a clearer framework for evaluating which claims can be challenged in IPR without estoppel exposure.